Movement disorders after stroke in adults: a review.

Bansil S, Prakash N, Kaye J, Wrigley S, Manata C, Stevens-Haas C, Kurlan R.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-42-195-1. doi: 10.7916/D86W98TB.

Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.

Santos-García D, de la Fuente-Fernández R, Valldeoriola F, Palasí A, Carrillo F, Grande M, Mir P, De Fabregues O, Casanova J.

J Neurol. 2012 Aug;259(8):1668-72. doi: 10.1007/s00415-011-6396-z. Review.

Dissecting the effects of disease and treatment on impulsivity in Parkinson's disease.

Simioni AC, Dagher A, Fellows LK.

J Int Neuropsychol Soc. 2012 Nov;18(6):942-51. doi: 10.1017/S135561771200094X.

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. Review.

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R.

Mult Scler. 2012 Feb;18(2):219-28. doi: 10.1177/1352458511419700.

Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.

Golla RM, Li M, Shen Y, Ji M, Yan Y, Fu K, Greiner TC, McKeithan TW, Chan WC.

Hematol Oncol. 2012 Dec;30(4):175-9. doi: 10.1002/hon.1020.

Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration.

Abu-Mugheisib M, Benecke R, Zettl UK.

Curr Pharm Des. 2012;18(29):4564-9. Review.

Inactivation of the parietal reach region causes optic ataxia, impairing reaches but not saccades.

Hwang EJ, Hauschild M, Wilke M, Andersen RA.

Neuron. 2012 Dec 6;76(5):1021-9. doi: 10.1016/j.neuron.2012.10.030.

A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease.

Miller JP, Yates BE, Al-Ramahi I, Berman AE, Sanhueza M, Kim E, de Haro M, DeGiacomo F, Torcassi C, Holcomb J, Gafni J, Mooney SD, Botas J, Ellerby LM, Hughes RE.

PLoS Genet. 2012;8(11):e1003042. doi: 10.1371/journal.pgen.1003042.

[Advance in studies on pathological mechanism of Parkinson's disease and traditional Chinese medicine experiments in prevention and treatment of Parkinson's disease].

Xiong P, Chen X, Zhang N.

Zhongguo Zhong Yao Za Zhi. 2012 Mar;37(5):686-91. Review. Chinese.

Toward a network model of dystonia.

Hendrix CM, Vitek JL.

Ann N Y Acad Sci. 2012 Aug;1265:46-55. doi: 10.1111/j.1749-6632.2012.06692.x.

Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease.

Knebel W, Rao N, Uchimura T, Mori A, Fisher J, Gastonguay MR, Chaikin P.

J Clin Pharmacol. 2012 Oct;52(10):1468-81.

Sexual behavior, body image, and partnership in chronic illness: a comparison of Huntington's disease and multiple sclerosis.

Reininghaus E, Reininghaus B, Fitz W, Hecht K, Bonelli RM.

J Nerv Ment Dis. 2012 Aug;200(8):716-20. doi: 10.1097/NMD.0b013e318261410f.

Effectiveness of clozapine in treating severe tardive dystonia and associated pyosis.

Pinninti NR, Desantis MJ, Adityanjee A.

J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):E5-6. doi: 10.1176/appi.neuropsych.11010020. No abstract available.

Cognition, coping, and outcome in Parkinson's disease.

Hurt CS, Landau S, Burn DJ, Hindle JV, Samuel M, Wilson K, Brown RG; PROMS-PD Study Group..

Int Psychogeriatr. 2012 Oct;24(10):1656-63. doi: 10.1017/S1041610212000749.